Sam Slutsky is ranked #1650 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

LIFE

Sam Slutsky

Q: How accurate are Sam Slutsky's stock ratings?

About 45% of Sam's ratings were profitable over a one-year hold, with an average return of -0.2% per rating, measured by 13Foresight from historical prices.

LifeSci Capital

Wall Street Analyst

★★★☆☆

#1650

on 13Foresight · ranked by our own returns

45%

Success Rate

-0.2%

Average Return

48 of 107 calls profitable · -151.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 45% of Sam Slutsky's ratings turned a profit when each position was held for 1 year — averaging -0.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

234 Buy 16 Hold 0 Sell

Sam's Stock Coverage 24 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
AVBP ArriVent BioPharma, Inc.	Oct 06, 2026	BUY	Strong Buy +89.4% avg upside 15 analysts	$15.00 0.80% Upside	-14.6%	·
CLDX Celldex	Oct 03, 2026	BUY	Strong Buy +42.9% avg upside 28 analysts	$64.00 112.71% Upside	-11.5%	·
TSE:EPRX Eupraxia Pharmaceuticals	Sep 30, 2026	BUY	Strong Buy +122.3% avg upside 11 analysts	$22.43 135.55% Upside	-25.2%	·
IRLA IRulya Therapeutics	Sep 30, 2026	BUY	Buy +434.4% avg upside 19 analysts	$98.00 197.50% Upside	-0.0%	·
DBVT DBV Technologies SA - American	Sep 30, 2026	BUY	Buy +143.7% avg upside 15 analysts	$45.00 374.23% Upside	+1.1%	·
OBX Obsidian Therapeutics	Sep 29, 2026	BUY	Strong Buy +14.6% avg upside 11 analysts	$43.00 190.66% Upside	-14.8%	·
IMVT Immunovant	Sep 26, 2026	BUY	Strong Buy +38.4% avg upside 25 analysts	$53.00 81.68% Upside	+2.7%	·
PYXS Pyxis Oncology	Sep 26, 2026	BUY	Strong Buy +349.6% avg upside 15 analysts	$8.00 341.90% Upside	-47.2%	·
ORKA Oruka Therapeutics	Sep 23, 2026	BUY	Strong Buy +37.2% avg upside 16 analysts	$175.00 80.59% Upside	+16.9%	·
ABVX Abivax SA Sponsored ADR	Sep 22, 2026	BUY	Strong Buy +54.7% avg upside 16 analysts	$168.00 94.10% Upside	-10.8%	·
OLMA Olema Pharmaceuticals	Sep 19, 2026	BUY	Strong Buy +401.3% avg upside 16 analysts	$16.00 128.64% Upside	-20.2%	·
DMRA Damora Therapeutics	Sep 18, 2026	BUY	Strong Buy +39.9% avg upside 20 analysts	$45.00 109.44% Upside	+4.9%	·
COGT Cogent Biosciences	Sep 15, 2026	BUY	Strong Buy +24.4% avg upside 26 analysts	$55.00 77.22% Upside	-12.2%	·
IMUX Immunic	Sep 11, 2026	BUY	Strong Buy +399.8% avg upside 23 analysts	$56.00 645.64% Upside	-32.6%	·
SYRE Spyre Therapeutics	Sep 08, 2026	BUY	Strong Buy +0.9% avg upside 25 analysts	$116.00 20.14% Upside	+12.6%	·
ATTO Attovia Therapeutics, Inc.	Sep 05, 2026	BUY	Strong Buy +161.7% avg upside 4 analysts	$45.00 196.25% Upside	-36.6%	·
TCRX TScan Therapeutics	Sep 02, 2026	HOLD	Strong Buy +4293.5% avg upside 12 analysts	—	-57.9%	·
ELVN Enliven Therapeutics	Aug 08, 2026	BUY	Strong Buy +40.0% avg upside 18 analysts	$70.00 58.20% Upside	-20.0%	·
CGON CG Oncology, Inc.	Aug 07, 2026	BUY	Strong Buy +33.1% avg upside 17 analysts	$108.00 66.94% Upside	-4.9%	·
ALXO ALX Oncology Holdings	Aug 06, 2026	HOLD	Strong Buy +1370.9% avg upside 11 analysts	—	-50.2%	·
IFRX InflaRx	Aug 06, 2026	BUY	Strong Buy +430.1% avg upside 12 analysts	$5.00 201.20% Upside	-31.4%	·
PVLA Palvella Therapeutics	Aug 05, 2026	BUY	Strong Buy +17.8% avg upside 28 analysts	$236.00 61.55% Upside	-2.7%	·
OKUR OnKure Therapeutics	Aug 05, 2026	BUY	Buy +743.5% avg upside 13 analysts	$16.00 510.63% Upside	-28.6%	·
GYRE Gyre Therapeutics	Aug 09, 2023	HOLD	Strong Buy +354.4% avg upside 15 analysts	—	+103.9%	·

🔒 19 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Sam Slutsky — Frequently Asked Questions

How accurate are Sam Slutsky's stock ratings?

Based on the calls 13Foresight could measure, about 45% of Sam's ratings were profitable over a one-year hold, with an average return of -0.2% per rating, or -151.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Sam ranked on 13Foresight?

Sam Slutsky is currently ranked #1650 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Sam cover?

Sam most recently has ratings on AVBP, CLDX, TSE:EPRX, IRLA, DBVT, OBX, IMVT, PYXS, ORKA, ABVX, OLMA, DMRA and 12 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Sam Slutsky

Rating Distribution

Welcome to 13Foresight!